PRTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Prothena has the Momentum Rank of 6.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Prothena's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Prothena's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Prothena's Momentum Rank falls into.
Thank you for viewing the detailed overview of Prothena's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Karin L Walker | officer: See Remarks | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Brandon S. Smith | officer: Chief Operating Officer | C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Carol D. Karp | officer: Chief Regulatory Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Michael J Malecek | officer: Chief Legal Officer | C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Hideki Garren | officer: Chief Medical Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Wagner M. Zago | officer: Chief Scientific Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Dennis J. Selkoe | director | 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Helen Susan Kim | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Tran Nguyen | officer: Chief Financial Officer | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Gene G. Kinney | officer: CSO & Head of R&D | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Dunn William H. Jr. | director | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Shane Cooke | director | TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000 |
Richard T Collier | director | |
Lars Ekman | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Paula K Cobb | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 05-19-2023
By Business Wire • 07-27-2023
By GuruFocus Research • 12-01-2023
By GuruFocus Research GuruFocus Editor • 05-18-2023
By Business Wire Business Wire • 04-24-2023
By Business Wire Business Wire • 02-16-2023
By Business Wire Business Wire • 05-16-2023
By Business Wire • 08-31-2023
By GuruFocus Research • 10-26-2023
By GuruFocus Research • 09-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.